Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | CTRC | Q99895 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950663 | 0.92 | ELANE (0.55) | ELANENPC1RAB9ACASP1F2 | |
| SCHEMBL2801908 | 0.87 | ELANE (0.55) | ELANENPC1RAB9ACASP1CTRC | |
| SCHEMBL7703522 | 0.83 | NPC1 (0.52) | ELANENPC1RAB9ACASP1F2 | |
| SCHEMBL7027446 | 0.82 | ELANE (0.55) | ELANENPC1RAB9ACASP1F2 | |
| SCHEMBL8642645 | 0.81 | NPC1 (0.60) | ELANENPC1RAB9ACASP1F2 | |
| SCHEMBL1039441 | 0.81 | NPC1 (0.54) | ELANENPC1RAB9ACASP1CTRC | |
| SCHEMBL1039440 | 0.81 | NPC1 (0.54) | ELANENPC1RAB9ACASP1CTRC | |
| SCHEMBL948869 | 0.79 | ELANE (0.56) | ELANENPC1RAB9ACASP1CTRC | |
| SCHEMBL6850665 | 0.79 | F2 (0.55) | F2PRSS1 | |
| SCHEMBL27501507 | 0.78 | ELANE (0.62) | ELANENPC1RAB9ACASP1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | DENDREON PHARMACEUTICALS LLC | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | F2, SERPINC1, F2RL3 | ELANE 167/4885NPC1 4467/4885RAB9A 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.